USANew treatments and approvals
Sepiapterin approved in the USA for phenylketonuria; EU approval also in place
A decision by a medicines regulator (FDA, European Commission, etc.). The regulator has reviewed the clinical studies behind the drug. For accelerated or conditional approvals, the lasting benefit is still being confirmed.
The FDA has approved sepiapterin for the treatment of phenylketonuria. The drug is meant to lower high phenylalanine levels in the blood. It is used in patients who respond to sepiapterin. The approval covers infants aged 1 month and older, children and adults. The approval is based on the phase 3 APHENITY study and long-term extension data. According to the company, the drug had also recently been authorized by the European Commission.
What does it mean for patients and families?
A new oral option that can be used alongside diet. Not everyone may respond to this drug. Access in Türkiye depends on TİTCK (Turkish Medicines and Medical Devices Agency) and SGK (Social Security Institution) processes.
Source
PTC Therapeutics (SEC dosyası) · source page
The source page was opened and read on October 7, 2026. Summary prepared by the Doktorclub editorial team and translated from Turkish; it has not yet been reviewed by a physician (a scientific board is being set up).
This page is translated from the Turkish original.
Related disease: Phenylketonuria (PKU)
This page reports a development; it is not a treatment recommendation. Your doctor decides whether a treatment is right for you.